Science or fiction: Use of nesiritide as a first-line agent?

Pharmacotherapy

Volumn 23, Issue 8, 2003, Pages 1081-1083

  Noviasky, John A ^a   Kelberman, Michael ^b   Whalen, Karen M ^c   Guharoy, Roy ^d   Darko, William ^d  

^a St Elizabeth Medical Center   (United States)

^b Mohawk Valley Water Authority   (United States)

^c St Joseph's Hospital   (United States)

^d SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; NESIRITIDE;

ABDOMINAL PAIN; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG CHOICE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEADACHE; HEALTH CARE COST; HEART FAILURE; HUMAN; LONG TERM CARE; LUNG CAPILLARY PRESSURE; REVIEW; RISK ASSESSMENT; SIDE EFFECT;

ACUTE DISEASE; HEALTH CARE COSTS; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NITROGLYCERIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0041347948     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.8.1081.32882     Document Type: Review

References (12)

1. Hobbs RE, Mills RM, Young JB. An update on nesiritide for treatment of decompensated heart failure. Expert Opin Investig Drugs 2001;10(5):935-42.
2. The Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. JAMA 2002;287:1531-40.
3. Bettencourt P. Brain natriuretic peptide (nesiritide) in the treatment of heart failure. Cardiovasc Drug Rev 2002;20(1):27-36.
4. Skrabal MZ, Stading JA, Behmer-Miller KA, Hilleman DE. Advances in the treatment of congestive heart failure: new approaches for an old disease. Pharmacotherapy 2000;20(7):787-804.
5. Keating GM, Goa KL. Nesiritide: a review of its use in acute decompensated heart failure. Drugs 2003;63(1):47-70.
6. Mills RM, Hobbs RE, Young JB. "BNP" for heart failure: role of nesiritide in cardiovascular therapeutics. Congest Heart Fail 2002;8(5):270-3.
7. Karkowsky A. Supplement to medical review, NDA 20-920. Part 2 is available from http://www.fda.gov/cder/foi/nda/ 2001/20-920_Natrecor_medr_P2.pdf. Part 3 is available from http://www.fda.gov/cder/foi/nda/2001/20-920 Natrecor_medr_P3.pdf. Accessed April 9, 2003.
8. Hung J. Statistical review, NDA 20-920. Available from http://www.fda.gov/cder/foi/nda/2001/20-920_Natrecor_statr. pdf. Accessed April 9, 2003.
9. Stevenson LW. The effects of nesiritide and intravenous nitroglycerin on pulmonary and systemic pressures in decompensated heart failure [abstr]. Presented at the American Heart Association Scientific Sessions, Anaheim, CA, November 11-14, 2001.
10. Anonymous. Nesiritide. Greenwood Village, CO: Micromedex healthcare series 2002, vol 115.
11. Anonymous. Nesiritide for decompensated congestive heart failure. Med Lett Drugs Ther 2001;43(1118):100-1.
12. Van Cura JD. Nesiritide utilization and protocol development [abstr]. Pharmacotherapy 2002;22(10):1359.